frontiers | Frontiers in Immunology

TYPE Correction
PUBLISHED 22 May 2023
DOI 10.3389/fimmu.2023.1219757

OPEN ACCESS

EDITED AND REVIEWED BY
Takaji Matsutani,
Repertoire Genesis, Inc., Japan

*CORRESPONDENCE
Guangyu Ma
mgy301@163.com
Ruimin Wang
wrm@yeah.net
Shichun Lu
lusc_301@163.com

†These authors have contributed equally to this work

RECEIVED 09 May 2023
ACCEPTED 12 May 2023
PUBLISHED 22 May 2023

CITATION
Wang G, Zhang W, Luan X, Wang Z, Liu J, Xu X, Zhang J, Xu B, Lu S, Wang R and Ma G (2023) Corrigendum: The role of 18F–FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.
Front. Immunol. 14:1219757.
doi: 10.3389/fimmu.2023.1219757

Corrigendum: The role of 18F–FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy

Guanyun Wang[1,2†], Wenwen Zhang[3†], Xiaohui Luan[1,4], Zhanbo Wang[5], Jiajin Liu[1], Xiaodan Xu[1], Jinming Zhang[1], Baixuan Xu[1], Shichun Lu[3*], Ruimin Wang[1*] and Guangyu Ma[1*]

[1]Department of Nuclear Medicine, The First Medical Centre, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China, [2]Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China, [3]Faculty of Hepato-Pancreato-Biliary Surgery, Chinese People's Liberation Army (PLA) General Hospital/Institute of Hepatobiliary Surgery of Chinese People's Liberation Army/Key Laboratory of Digital Hepetobiliary Surgery, People's Liberation Army, Beijing, China, [4]Graduate School, Medical School of Chinese People's Liberation Army (PLA), Beijing, China, [5]Department of Pathology, The First Medical Centre, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China

KEYWORDS

unresectable hepatocellular carcinoma, conversion therapy, major pathological response, prognosis, ^{18}F-FDG PET

A corrigendum on

The role of 18F–FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy

by Wang G, Zhang W, Luan X, Wang Z, Liu J, Xu X, Zhang J, Xu B, Lu S, Wang R and Ma G (2023). *Front. Immunol.* 14:1151967. doi: 10.3389/fimmu.2023.1151967

In the published article, there was an error in the formula in the manuscript.

A correction has been made to **Materials and Methods**, Image analysis, Paragraph 2. This sentence previously stated:

"The percentages of post-treatment changes in metabolic parameters were calculated as follows:

$$\Delta\text{SUVmax}\,(\,\%\,) = \frac{\text{SUVmax of pre-treatment} - \text{SUVmax of post-treatment}}{\text{SUVmax of pretreatment}} \times 100\,\%$$

$$\Delta\text{TLR}(\,\%\,) = \frac{\text{TLR of pre-treatment} - \text{TLR of post-treatment}}{\text{TLR of pre-treatment}} \times 100\,\%$$

$$\Delta PLR(\%) = \frac{\text{PLR of pre-treatment} - \text{PLR of post-treatment}}{\text{PLR of pre-treatment}} \times 100\%"$$

The corrected sentence appears below:

"The percentages of post-treatment changes in metabolic parameters were calculated as follows:

$$\Delta SUVmax(\%) = \frac{\text{SUVmax of post-treatment} - \text{SUVmax of pre-treatment}}{\text{SUVmax of pre-treatment}} \times 100\%$$

$$\Delta TLR(\%) = \frac{\text{TLR of post-treatment} - \text{TLR of pre-treatment}}{\text{TLR of pre-treatment}} \times 100\%$$

$$\Delta PLR(\%) = \frac{\text{PLR of post-treatment} - \text{PLR of pre-treatment}}{\text{PLR of pre-treatment}} \times 100\%"$$

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note